Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 6 de 6
Filtrar
Más filtros











Base de datos
Intervalo de año de publicación
1.
Calcif Tissue Int ; 110(2): 204-214, 2022 02.
Artículo en Inglés | MEDLINE | ID: mdl-34495356

RESUMEN

Hypoparathyroidism is an orphan disease with ill-defined epidemiology that is subject to geographic variability. We conducted this study to assess the demographics, etiologic distribution, treatment patterns and complication frequency of patients with chronic hypoparathyroidism in Turkey. This is a retrospective, cross-sectional database study, with collaboration of 30 endocrinology centers located in 20 cities across seven geographical regions of Turkey. A total of 830 adults (mean age 49.6 ± 13.5 years; female 81.2%) with hypoparathyroidism (mean duration 9.7 ± 9.0 years) were included in the final analysis. Hypoparathyroidism was predominantly surgery-induced (n = 686, 82.6%). The insulting surgeries was carried out mostly due to benign causes in postsurgical group (SG) (n = 504, 73.5%) while patients in nonsurgical group (NSG) was most frequently classified as idiopathic (n = 103, 71.5%). The treatment was highly dependent on calcium salts (n = 771, 92.9%), calcitriol (n = 786, 94.7%) and to a lower extent cholecalciferol use (n = 635, 76.5%) while the rate of parathyroid hormone (n = 2, 0.2%) use was low. Serum calcium levels were most frequently kept in the normal range (sCa 8.5-10.5 mg/dL, n = 383, 46.1%) which might be higher than desired for this patient group. NSG had a lower mean plasma PTH concentration (6.42 ± 5.53 vs. 9.09 ± 7.08 ng/l, p < 0.0001), higher daily intake of elementary calcium (2038 ± 1214 vs. 1846 ± 1355 mg/day, p = 0.0193) and calcitriol (0.78 ± 0.39 vs. 0.69 ± 0.38 mcg/day, p = 0.0057), a higher rate of chronic renal disease (9.7% vs. 3.6%, p = 0.0017), epilepsy (6.3% vs. 1.6%, p = 0.0009), intracranial calcifications (11.8% vs. 7.3%, p < 0.0001) and cataracts (22.2% vs. 13.7%, p = 0.0096) compared to SG. In conclusion, postsurgical hypoparathyroidism is the dominant etiology of hypoparathyroidism in Turkey while the nonsurgical patients have a higher disease burden with greater need for medications and increased risk of complications than the postsurgical patients.


Asunto(s)
Hipocalcemia , Hipoparatiroidismo , Adulto , Calcio , Femenino , Humanos , Hipoparatiroidismo/epidemiología , Persona de Mediana Edad , Hormona Paratiroidea , Estudios Retrospectivos , Turquía/epidemiología
2.
Gynecol Endocrinol ; 35(8): 714-718, 2019 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-30896318

RESUMEN

Dipeptidyl peptidase-4 (DPP-4) plays a role in metabolic and inflammatory diseases. Increased adenosine deaminase (ADA) has been suggested to induce insulin resistance and inflammation. We measured serum DPP-4 and ADA activities. Serum ADA activity was significantly higher in PCOS group (p = .006), whereas there was no difference in serum DPP-4 activity between the groups (p > .05). When the study subjects were divided into four groups in terms of obesity; an increasing trend in serum ADA activity between the groups was observed and ADA activity was significantly higher in overweight and obese patients with PCOS than nonobese controls (p = .016), there were no significant differences between the other groups (p > .05). A positive correlation was found between ADA and BMI in the whole group (p = .022). Multivariate regression analyses revealed that significant determinants were diastolic blood pressure, ADA, and the presence of PCOS for DPP-4 (R2 = 0.344, F = 9.079, p < .001); the presence of PCOS and DPP-4 for ADA (R2 = 0.123, F = 6.302, p = .003). We demonstrated increased serum ADA activity as well as its association with obesity in PCOS, while there was no change in serum DPP-4 activity in women with PCOS.


Asunto(s)
Adenosina Desaminasa/sangre , Dipeptidil Peptidasa 4/sangre , Obesidad/sangre , Obesidad/complicaciones , Síndrome del Ovario Poliquístico/sangre , Síndrome del Ovario Poliquístico/complicaciones , Adenosina Desaminasa/metabolismo , Adulto , Índice de Masa Corporal , Estudios de Casos y Controles , Dipeptidil Peptidasa 4/metabolismo , Femenino , Humanos , Resistencia a la Insulina/fisiología , Adulto Joven
3.
Calcif Tissue Int ; 99(4): 365-72, 2016 10.
Artículo en Inglés | MEDLINE | ID: mdl-27328677

RESUMEN

Hypothyroidism is associated with changes in bone metabolism. The impact of hypothyroidism and the associated autoimmunity on the mediators of bone turnover in Hashimoto's thyroiditis (HT) is not known. In this study, we assessed the levels of OPG, RANKL, and IL-6 along with markers of bone formation as osteocalcin (OC) and markers of bone resorption as type 1 collagen C telopeptide (CTX) and tartrate-resistant acid phosphatase isoform 5b (TRAcP 5b) in 30 hypothyroid and 30 euthyroid premenopausal HT patients and 20 healthy premenopausal controls. We found that TRAcP 5b (p = 0.006), CTX (p = 0.01), OC (p = 0.017), and IL-6 (p < 0.001) levels were lower in the hypothyroid group compared to euthyroid HT patients and controls. OPG levels were higher (p < 0.001) and RANKL levels were lower (p = 0.021) in hypothyroid and euthyroid HT patients compared to controls. TSH was negatively correlated with IL-6 (rho = -0.434, p < 0.001), OC (rho = -0.313, p = 0.006), TRAcP 5b (rho = -0.335, p = 0.003), and positively correlated with OPG (rho = 0.248, p = 0.029). RANKL/OPG ratio was independently associated with the presence of HT. In conclusion, bone turnover is slowed down by hypothyroidism in premenopausal patients with HT. Thyroid autoimmunity might have a unique impact on OPG/RANKL levels apart from the resultant hypothyroidism.


Asunto(s)
Remodelación Ósea , Enfermedad de Hashimoto/inmunología , Interleucina-6/metabolismo , Osteoprotegerina/metabolismo , Ligando RANK/metabolismo , Adulto , Autoinmunidad , Índice de Masa Corporal , Huesos/metabolismo , Colágeno Tipo I/metabolismo , Estudios Transversales , Femenino , Enfermedad de Hashimoto/sangre , Humanos , Hipotiroidismo/metabolismo , Persona de Mediana Edad , Péptidos/metabolismo , Premenopausia , Factores de Riesgo , Fosfatasa Ácida Tartratorresistente/metabolismo , Glándula Tiroides/metabolismo , Ultrasonografía
4.
Cytokine ; 80: 13-7, 2016 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-26928603

RESUMEN

The disrupted autoimmune response in Hashimoto's thyroiditis (HT) has long been considered to be dominantly T helper type 1 (Th1) mediated. Recent advances in the field of immunology have introduced a new class of effector T cells, named 'Th17', which plays important roles in autoimmune disorders once thought to be merely Th1 mediated. We aimed to examine the levels of major Th17 cytokines in patients with HT in this study. We studied serum interleukin 17 (IL-17) and interleukin 23 (IL-23) levels in 46 newly diagnosed, untreated patients with HT (40 women and 6 men, aged 40.0 ± 11.8 years) divided into euthyroid (n=22) and hypothyroid (n=24) groups and compared them with age and sex matched 26 healthy euthyroid controls without HT (21 women and 5 men; aged 36.0 ± 12.9 years). Serum IL-17 and IL-23 levels were significantly different among euthyroid and hypothyroid HT patients and controls, with highest levels obtained in the euthyroid HT group (p=0.041 for IL-17 and p<0.001 for IL-23). TSH was negatively and FT4 was positively correlated with IL-17 (p=0.016 for TSH and p=0.004 for FT4) and IL-23 (p<0.001 for TSH and p=0.003 for FT4) levels. There were no correlations between thyroid volumes calculated on thyroid ultrasonography and IL-17 (p=0.630) or IL-23 (p=0.321) levels. In conclusion, the levels of IL-17, one of the major effector cytokines of the Th17 system, and IL-23, which had been implicated in the generation, survival and expansion of Th17 cells, are altered in HT. How thyroid hormone status and the course of disease affect Th17 system in chronic autoimmune thyroiditis needs to be determined with further studies.


Asunto(s)
Enfermedad de Hashimoto/inmunología , Enfermedad de Hashimoto/fisiopatología , Interleucina-17/sangre , Interleucina-23/sangre , Adulto , Autoinmunidad , Femenino , Enfermedad de Hashimoto/sangre , Humanos , Hipotiroidismo/inmunología , Hipotiroidismo/fisiopatología , Masculino , Persona de Mediana Edad , Células Th17/inmunología , Glándula Tiroides/diagnóstico por imagen , Tirotropina/sangre , Ultrasonografía , Adulto Joven
5.
Med Oral Patol Oral Cir Bucal ; 19(1): e1-7, 2014 Jan 01.
Artículo en Inglés | MEDLINE | ID: mdl-23986010

RESUMEN

OBJECTIVES: Acromegaly is a metabolic disorder caused by increased growth hormone secretion. As a consequence of acromegaly some typical craniofacial morphology changes appear. This pilot study was conducted to compare the bite force and the characteristic size and shape of the craniofacial components of acromegalic patients with the healthy Turkish individuals. In addition, the correlations between bite force and craniofacial morphology of patients with acromegaly and control individuals were evaluated. STUDY DESIGN: The maximum bite force of the participants was recorded with strain-gage transducer. Lateral x-ray scans were made under standard conditions, in centric occlusion. On cephalograms, the linear and angular measurements was performed. RESULTS: Patients with acromegaly showed increased anterior and posterior total face height, ramus length, width of frontal sinuses, gonial angle and a negative difference between maxillary and mandibular protrusions. In addition, females with acromegaly showed larger lower anterior face height and sella turcica, decreased facial angle, increased mandibular plane angle. The cephalometric measurements, except one did not showed correlation with the bite force in acromegalic patients. In control group, significant correlations were observed between anterior total face height and anterior lower face height, mandibular plane angle and gonial angle. CONCLUSIONS: The greater changes were observed in the mandible. The maximum bite force of patients with acromegaly showed no difference from healthy individuals. The non-significant difference of bite force between healthy participants and acromegalic patients provide important information for dental treatment and prosthetic rehabilitation of acromegalic patients.


Asunto(s)
Acromegalia/complicaciones , Acromegalia/fisiopatología , Fuerza de la Mordida , Anomalías Craneofaciales/etiología , Anomalías Craneofaciales/fisiopatología , Cefalometría , Femenino , Humanos , Masculino , Proyectos Piloto
6.
Rheumatol Int ; 28(4): 367-70, 2008 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-17687556

RESUMEN

Secondary amyloidosis (AA amyloidosis) has rarely been described in patients with systemic lupus erythematosus (SLE). We, herein, present a 56-year-old female patient, who developed AA amyloidosis following a 22-year history of SLE. She developed severe mitral regurgitation complicated with chordae tendinea rupture that led to acute congestive heart failure and went on a mitral valve replacement, where no flare symptoms of SLE were present. Three months after the operation, she presented with a nephrotic-range proteinuria, acute renal failure, and severe sepsis. She was found to have new vegetations on replaced valve and multi-organ failure caused her death. Re-evaluation of the excised mitral valve revealed AA amyloid deposition. Post-mortem biopsies from the kidney and bone marrow also revealed secondary amyloidosis.


Asunto(s)
Amiloidosis/diagnóstico , Lupus Eritematoso Sistémico/complicaciones , Insuficiencia de la Válvula Mitral/etiología , Insuficiencia Multiorgánica/etiología , Síndrome Nefrótico/etiología , Choque Séptico/etiología , Lesión Renal Aguda/etiología , Amiloidosis/complicaciones , Amiloidosis/etiología , Amiloidosis/patología , Cuerdas Tendinosas , Resultado Fatal , Femenino , Insuficiencia Cardíaca/etiología , Rotura Cardíaca/etiología , Implantación de Prótesis de Válvulas Cardíacas , Humanos , Lupus Eritematoso Sistémico/patología , Persona de Mediana Edad , Insuficiencia de la Válvula Mitral/complicaciones , Insuficiencia de la Válvula Mitral/patología , Insuficiencia de la Válvula Mitral/cirugía , Insuficiencia Multiorgánica/patología , Síndrome Nefrótico/complicaciones , Síndrome Nefrótico/patología , Choque Séptico/patología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA